1 Gene Editing Stock to Buy Now, and 1 to Sell
In our modern age, the power of gene editing is undeniable. After years of foundational scientific research, it's now becoming possible to treat illnesses that were until very recently intractable. And (as is usually the case during periods of great innovation), there's plenty of money to be made from winners of the future if an investor chooses carefully.
On that note, let's look at one gene-editing stock that could be going places, and one that's likely to languish.
One stock with an encouraging outlook is gene-editing biotech Caribou Biosciences (NASDAQ: CRBU). The Berkeley, California-based company has two cancer programs in phase 1 trials: one for relapsed or refractory B-cell non-Hodgkin lymphoma, and another to treat relapsed or refractory multiple myeloma.
Source Fool.com
